Genenta Science S.p.A.

Develops cell & gene therapies using engineered stem cells to treat solid tumors.

GNTA | US

Overview

Corporate Details

ISIN(s):: US36870W1009
LEI:
Country:: United States of America
Address:: OLGETTINA, NO. 58, 20132 MILAN
Website:: https://www.genenta.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Genenta Science S.p.A. is a clinical-stage immuno-oncology company developing proprietary cell and gene therapies for the treatment of solid tumors. The company's technology is centered on engineering a patient's own hematopoietic stem cells using a lentiviral vector to combat cancer. Its lead candidate, Temferon, is designed to make tumors visible to the immune system by reprogramming the tumor microenvironment and breaking immune tolerance. Genenta has completed a Phase 1 clinical trial in Glioblastoma Multiforme and has initiated a Phase 1/2a study in metastatic Renal Cell Carcinoma. The treatments are designed as one-time monotherapies that also have the potential to be used in combination to enhance the efficacy of other therapeutics, such as immune checkpoint inhibitors.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Genenta Science S.p.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Genenta Science S.p.A.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Genenta Science S.p.A. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Pluri Inc. Develops placenta-based cell therapeutics using a proprietary 3D cell-expansion platform.	Israel	PLUR
PLUS THERAPEUTICS, INC. Developing targeted radiotherapeutics for hard-to-treat cancers like glioblastoma and solid tumors.	United States of America	PSTV
PMV Pharmaceuticals, Inc. Developing small molecule therapies targeting p53 mutations to treat cancer.	United States of America	PMVP
Polaris AI Pharma Corp. A global supplier of generic APIs using AI to accelerate drug development.	South Korea	041910
Poltreg S.A. Pioneering T-regulatory cell therapies for autoimmune diseases like diabetes, MS, and ALS.	Poland	PTG
PolyPeptide Group AG A global CDMO specializing in peptide and oligonucleotide APIs for pharma and biotech partners.	Switzerland	PPGN
PolyPid Ltd. Develops localized, prolonged-release drug therapies for surgery, oncology & metabolic diseases.	United States of America	PYPD
Praxis Precision Medicines, Inc. Developing therapies for CNS disorders using insights from genetic epilepsies.	United States of America	PRAX
PRECIGEN, INC. Develops gene and cell therapies for difficult-to-treat diseases using precision technology.	United States of America	PGEN
Precipio, Inc. Provides blood cancer diagnostic services & products to improve accuracy for physicians & labs.	United States of America	PRPO